new-onset atrial fibrillation
Conditions
Interventions
Control group:5% glucose solution
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged>= 18 years; 2. Accept elective cardiopulmonary bypass coronary artery bypass grafting; 3. Sinus rhythm; 4. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with poor compliance, or patients who cannot complete long-term follow-up, or patients who have not received elective CPB coronary artery bypass grafting; 2. History of atrial fibrillation or amiodarone treatment within half a year before surgery; 3. History of arrhythmia or taking antiarrhythmic drugs other than beta-blockers or calcium channel blockers within half a year before surgery; 4. Allergic to iodine, amiodarone or its excipients; 5. Patients with implanted cardioverter-defibrillator or pacemaker; 6. Thyroid dysfunction; 7. Liver insufficiency (alanine aminotransferase or aspartate aminotransferase higher than 2 times the upper limit of normal); 8. Renal insufficiency (serum creatinine greater than 200 µmol/L); 9. Pulmonary fibrosis; 10. Corneal disease or severe vision loss or blindness; 11. The last blood potassium level before surgery is less than 3.5mmol/L; 12. Patients with definite diagnosis of severe valve disease, congenital heart disease or macrovascular disease who need other types of cardiac surgery except coronary artery bypass grafting; 13. Heart failure (left ventricular ejection fraction less than 30% indicated by the last echocardiogram before surgery); 14. Patients with sick sinus syndrome, severe bradycardia (heart rate less than 50bpm), second-degree or higher atrioventricular block; 15. Patients using mechanical life support before surgery, including intra-aortic balloon counterpulsation (IABP), extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), renal replacement therapy (CRRT); 16. Nursing or pregnant women; 17. Patients with mental or legal disabilities; 18. The patient is participating in another interventional clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of new-onset atrial fibrillation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative ICU stay time;length of hospital stay;postoperative complications;mortality; | — |
Countries
China
Contacts
Public ContactHu Shengshou
Fuwai Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed